Valuation: SENSORION

Market Cap 134M 153M 123M 115M 217M 14.58B 221M 1.48B 574M 7.16B 575M 562M 24.69B P/E 2026 *
-17.3x
P/E 2027 * -4x
Enterprise Value 1.83M 2.09M 1.68M 1.57M 2.97M 199M 3.01M 20.16M 7.84M 97.82M 7.85M 7.68M 337M EV / Sales 2026 *
0.08x
EV / Sales 2027 * 20.9x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 31/05/2026
Director of Finance/CFO - 25/06/2024
Chief Tech/Sci/R&D Officer - 10/12/2023
Director TitleAgeSince
Director/Board Member - 08/03/2015
Director/Board Member 43 -
Chairman 61 29/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
+1.70%+7.41%+2.50%+8.22% 49.92B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+8.30%+40.44% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+14.00%+19.59% 13.86B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +2.17%+5.82%+79.44%+120.52% 27.3B
Weighted average by Cap. +2.07%+6.53%+90.20%+137.91%

Financials

2026 *2027 *
Net sales 21.86M 25M 20.09M 18.72M 35.51M 2.38B 36.05M 241M 93.75M 1.17B 93.85M 91.84M 4.03B 6.4M 7.32M 5.88M 5.48M 10.39M 697M 10.55M 70.55M 27.43M 342M 27.46M 26.87M 1.18B
Net income -4.34M -4.96M -3.99M -3.72M -7.05M -473M -7.16M -47.88M -18.61M -232M -18.63M -18.23M -801M -50.64M -57.93M -46.54M -43.38M -82.28M -5.52B -83.53M -559M -217M -2.71B -217M -213M -9.34B
Net Debt -132M -151M -121M -113M -214M -14.38B -218M -1.46B -566M -7.07B -567M -555M -24.35B -
Logo SENSORION
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-